Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Leveraging the germ layer development patterns to predict prognosis and identify MEST as a novel therapeutic target in glioma.
PMID 41501725 · PMC12870398 · Cancer cell international · 2026 · 7 claims · 8 setups
MEST is a key oncogenic GLD-related gene and a novel therapeutic target in glioma, identified via a machine learning feature selection framework
-
Has reproduction · 80
Decoding the tumor microenvironment and molecular mechanism: unraveling cervical cancer subpopulations and prognostic signatures through scRNA-Seq and bulk RNA-seq analyses.
PMID 38482016 · PMC10933018 · Frontiers in immunology · 2024 · 8 claims · 8 setups
C3 PLP2+ Tumor Epithelial Progenitor Cells are a noteworthy subpopulation exerting a pivotal influence on CC differentiation and progression
-
Full-text index only
MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy.
PMID 39805182 · PMC11780959 · Translational oncology · 2025 · 6 claims · 8 setups
A C3 PCLAF+ tumor cell subtype identified by scRNA-seq shows high proliferation/differentiation potential and is linked to aggressive tumor behavior and poor prognosis in HR+BC
-
Full-text index only
Restoring immune homeostasis in atherosclerotic plaques via inorganic violet phosphorus nano-immunotherapy.
PMID 41494534 · PMC12866099 · Cell reports. Medicine · 2026 · 8 claims · 8 setups
VPNS@P selectively accumulates in immune cells within atherosclerotic plaques (predominantly macrophages and monocytes, partly T and B cells) with minimal off-target uptake by non-immune vascular cells
-
Full-text index only
Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.
PMID 39759507 · PMC11695424 · Frontiers in immunology · 2024 · 8 claims · 8 setups
A malignant cell subtype in PCa with high expression of NEFH was identified, located at the differentiation terminal, showing higher malignancy and association with advanced tumor lesions.